Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)

Trial Profile

Randomized, Phase II Study of Pembrolizumab (MK-3475) versus Chemotherapy in Patients with Advanced Melanoma (KEYNOTE 002)

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2019

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Dacarbazine; Paclitaxel; Temozolomide
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms KEYNOTE-002
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 22 Mar 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.
    • 10 Feb 2019 This trial has been completed in Spain according to European Clinical Trials Database record
    • 06 Feb 2019 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top